People living with mental health disorders who benefit from medication may try several types before finding a solution that helps manage their symptoms.
But what if a simple blood test could help doctors understand what medication might work best for patients at the start of their treatment?
That’s an idea gaining traction and the focus of new scientific findings from a University of Wisconsin–Madison collaboration featured in the journal Brain Behavior and Immunity.
The researchers have discovered a relationship between the levels of an immune system protein in blood and people’s response to a drug for the bipolar treatment
“This is unique because mental health treatments, especially in the area of bipolar depression, have been challenging to identify,” says Charles Raison, who led the analysis.
“One of the great holy grails in addition to finding new treatments, is to discover new ways of identifying which of the available treatments is most likely to benefit any given patient.”
The biomarker studied, called c-reactive protein (CRP), has been traditionally used to measure levels of inflammation in the body to better understand chronic medical diseases and autoimmune disorders.
For instance, previous work suggests that CRP levels may predict whether patients with non-bipolar major depression will respond to other types of interventions, such as serotonin-selective reuptake inhibitors (SSRIs) or psychotherapy.
In the current study, the team explored the effectiveness of a medication called lurasidone in 485 patients with bipolar disorder.
These people struggled with an episode of major depression (also known as bipolar depression).
People living with bipolar disorder experience extreme mood swings with periods of mania alternating with depression.
Participants in the six-week study were randomly assigned to take lurasidone (some taking 20-60 milligrams per day and others 80-120 milligrams) or a placebo pill.
At the time of the study, neither participants nor the scientists leading the research knew who was receiving the active drug versus the placebo.
As a group, participants who received lurasidone during the six week study period showed reduced depression compared to participants who received placebo.
However, when researchers took pre-treatment CRP levels into account, a striking pattern emerged.
In participants with higher levels of pretreatment CRP, lurasidone produced a large antidepressant benefit when compared to a placebo.
But in participants with low levels of CRP, lurasidone showed no advantage over the placebo.
If confirmed in future studies, these findings suggest that clinicians may be able to use a simple, inexpensive CRP blood test to determine which patients with bipolar depression could potentially benefit from the drug.
The fact that a person’s immune system may shape mental health reflects a more systemic understanding of the body compared to typical approaches in mental health practice and research.
In the future, Raison and colleagues hope to design studies that can more specifically predict the effectiveness of interventions based on CRP levels.
Source: University of Wisconsin-Madison.